QR Code

Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives

Sclerostin emerges as a novel target for bone anabolic therapy in bone diseases. Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone diseases in which therapeutic potential of sclerostin inhibition cannot be ignored. In OI, genetic/pharmacologic sclerostin inhibition promo...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Tao Xiaohui, Luyao Wang, Xin Yang, Hewen Jiang, Ning Zhang, Huarui Zhang, Dijie Li, Xiaofei Li, Yihao Zhang, Shenghang Wang, Chuanxin Zhong, Sifan Yu, Meishen Ren, Meiheng Sun, Nanxi Li, Tienan Chen, Yuan Ma, Fangfei Li, Jin Liu, Yuanyuan Yu, Hua Yue, Zhenlin Zhang, Ge Zhang
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2024-07-01
Rangatū:Journal of Orthopaedic Translation
Ngā marau:
Cardiovascular safety
Loops
Osteogenesis imperfecta (OI)
Sclerostin
Sclerostin inhibition
Therapeutic perspectives
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S2214031X24000469
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite